Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04703855
Other study ID # ABT-CIP-10382
Secondary ID CRD 1022
Status Terminated
Phase N/A
First received
Last updated
Start date July 14, 2021
Est. completion date June 30, 2022

Study information

Verified date July 2022
Source Abbott Medical Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hong Kong and Taiwan HM3 PMS is a prospective, single arm, post market surveillance is designed to evaluate clinical and functional outcomes with the HM3 LVAS as a treatment for advanced heart failure. The PMS will enroll approximately 30 patients, that meet the HM3 commercially approved labelling indications, from approximately 4 sites in Hong Kong and Taiwan. PMS participants will be followed until the 24 months follow-up visit or until they experience an outcome, whichever comes first.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date June 30, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patients at the participating sites that are determined to meet the HM3 commercially approved labelling indication and have a planned HM3 implant are eligible to participate in this PMS. Assessment for eligibility criteria is based on medical records of the site and interview with a candidate patient. Exclusion Criteria: None

Study Design


Related Conditions & MeSH terms


Intervention

Device:
HeartMate 3™ left ventricular assist system (HM3 LVAS)
Advanced heart failure patients will be implanted with the HM3 LVAS

Locations

Country Name City State
Hong Kong University of Hong Kong Hong Kong Pokfulam
Taiwan National Taiwan University Hospital Taipei City
Taiwan Tri-Service General Hospital Taipei City

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Countries where clinical trial is conducted

Hong Kong,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Efficacy Endpoint: Number of participants with overall survival to transplant, myocardial recovery or on device support free of debilitating stroke (Modified Rankin Score >3) or reoperation for pump replacement Overall survival to transplant, myocardial recovery or on device support free of debilitating stroke (Modified Rankin Score >3) or reoperation for pump replacement will be assessed using the Kaplan-Meier product-limit method along with a competing outcomes graph. Subjects who are urgently transplanted due to a HeartMate 3 malfunction will be considered to have experienced a primary endpoint event, as will subjects who expire, suffer a debilitating stroke or have their HeartMate 3 exchanged due to a device failure. Subjects who are transplanted (except as described above), explanted for recovery, withdraw from the trial or are lost to follow-up will be censored at that time in the analysis. Throughout the study (approximately 24 months post implant)
Primary Primary Safety Endpoint: Number of cumulative occurrence of adverse events Cumulative occurrence of adverse events will be presented as percent of patients with adverse events and events per patient year of support. Throughout the study (approximately 24 months post implant)
Secondary Mean change in Six-minute Walk Test from baseline The 6-minute Walk test will be conducted at all follow-up visits until the end of the surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in walking distance between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in walking distance over time. At 1 month post implant
Secondary Mean change in Six-minute Walk Test from baseline The 6-minute Walk test will be conducted at all follow-up visits until the end of the surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in walking distance between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in walking distance over time. At 3 months post implant
Secondary Mean change in Six-minute Walk Test from baseline The 6-minute Walk test will be conducted at all follow-up visits until the end of the surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in walking distance between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in walking distance over time. At 6 months post implant
Secondary Mean change in Six-minute Walk Test from baseline The 6-minute Walk test will be conducted at all follow-up visits until the end of the surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in walking distance between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in walking distance over time. At 12 months post implant
Secondary Mean change in Six-minute Walk Test from baseline The 6-minute Walk test will be conducted at all follow-up visits until the end of the surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in walking distance between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in walking distance over time. At 24 months post implant
Secondary Change proportion of New York Heart Association (NYHA) Functional Status from baseline Subjects' NYHA Functional Status will be assessed at all scheduled follow-up visits until the end of the surveillance period. Percent of subjects in each NYHA class will be presented for all follow-up visits. For comparison, patients will be grouped into NYHA Class I/II (No limitation and Slight limitation of physical activity) vs. NYHA Class III/IV (Marked limitation and Inability to carry out physical activities). McNemar's test will then be used to assess if there is an increase in proportion of Class I and II subjects at each visit comparing to the baseline. At 1 month post implant
Secondary Change proportion of New York Heart Association (NYHA) Functional Status from baseline Subjects' NYHA Functional Status will be assessed at all scheduled follow-up visits until the end of the surveillance period. Percent of subjects in each NYHA class will be presented for all follow-up visits. For comparison, patients will be grouped into NYHA Class I/II (No limitation and Slight limitation of physical activity) vs. NYHA Class III/IV (Marked limitation and Inability to carry out physical activities). McNemar's test will then be used to assess if there is an increase in proportion of Class I and II subjects at each visit comparing to the baseline. At 3 months post implant
Secondary Change proportion of New York Heart Association (NYHA) Functional Status from baseline Subjects' NYHA Functional Status will be assessed at all scheduled follow-up visits until the end of the surveillance period. Percent of subjects in each NYHA class will be presented for all follow-up visits. For comparison, patients will be grouped into NYHA Class I/II (No limitation and Slight limitation of physical activity) vs. NYHA Class III/IV (Marked limitation and Inability to carry out physical activities). McNemar's test will then be used to assess if there is an increase in proportion of Class I and II subjects at each visit comparing to the baseline. At 6 months post implant
Secondary Change proportion of New York Heart Association (NYHA) Functional Status from baseline Subjects' NYHA Functional Status will be assessed at all scheduled follow-up visits until the end of the surveillance period. Percent of subjects in each NYHA class will be presented for all follow-up visits. For comparison, patients will be grouped into NYHA Class I/II (No limitation and Slight limitation of physical activity) vs. NYHA Class III/IV (Marked limitation and Inability to carry out physical activities). McNemar's test will then be used to assess if there is an increase in proportion of Class I and II subjects at each visit comparing to the baseline. At 12 months post implant
Secondary Change proportion of New York Heart Association (NYHA) Functional Status from baseline Subjects' NYHA Functional Status will be assessed at all scheduled follow-up visits until the end of the surveillance period. Percent of subjects in each NYHA class will be presented for all follow-up visits. For comparison, patients will be grouped into NYHA Class I/II (No limitation and Slight limitation of physical activity) vs. NYHA Class III/IV (Marked limitation and Inability to carry out physical activities). McNemar's test will then be used to assess if there is an increase in proportion of Class I and II subjects at each visit comparing to the baseline. At 24 months post implant
Secondary Mean change in EQ-5D-5L quality of life (QoL) from baseline Subject's quality of life will be measured by the EQ-5D-5L QoL questionnaire at baseline and all visits after HM3 implant until the end of surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in QoL Score between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in QoL over time. At 1 month post implant
Secondary Mean change in EQ-5D-5L quality of life (QoL) from baseline Subject's quality of life will be measured by the EQ-5D-5L QoL questionnaire at baseline and all visits after HM3 implant until the end of surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in QoL Score between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in QoL over time. At 3 months post implant
Secondary Mean change in EQ-5D-5L quality of life (QoL) from baseline Subject's quality of life will be measured by the EQ-5D-5L QoL questionnaire at baseline and all visits after HM3 implant until the end of surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in QoL Score between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in QoL over time. At 6 months post implant
Secondary Mean change in EQ-5D-5L quality of life (QoL) from baseline Subject's quality of life will be measured by the EQ-5D-5L QoL questionnaire at baseline and all visits after HM3 implant until the end of surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in QoL Score between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in QoL over time. At 12 months post implant
Secondary Mean change in EQ-5D-5L quality of life (QoL) from baseline Subject's quality of life will be measured by the EQ-5D-5L QoL questionnaire at baseline and all visits after HM3 implant until the end of surveillance period. The overall mean, median, standard deviation, minimum and maximum will be presented for all follow-up visits. Differences in QoL Score between each visit and baseline will be calculated and assessed for improvements using paired, nonparametric Wilcoxon signed-rank test. In addition, box plots will be used to show changes in QoL over time. At 24 months post implant
Secondary Frequency of Rehospitalization and Reoperation Frequency and reason will be reported for rehospitalization and reoperation. Freedom from rehospitalization and reoperation will be assessed using the Kaplan-Meier product-limit method. Throughout the study (approximately 24 months post implant)
Secondary Number of participants with Device Malfunctions All suspected HM3 device malfunctions will be reported. Data on device malfunctions will be analyzed for the following:
The component of the device involved
Days to the malfunction
Action taken in response to the malfunction
Reoperations due to malfunction
Death due to malfunction
Throughout the study (approximately 24 months post implant)
See also
  Status Clinical Trial Phase
Suspended NCT02962973 - European Clinical Evaluation of the Carmat Total Artificial Heart N/A
Recruiting NCT04915924 - Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea N/A
Completed NCT01626404 - Screening for Advanced Heart Failure Treatment (SEE-HF)
Withdrawn NCT00572286 - Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study N/A
Completed NCT00690157 - Registry of Patients Referred for Heart Transplantation N/A
Active, not recruiting NCT03874312 - Ultrasound-assessed Internal Jugular Vein Distensibility in Advanced Chronic Heart Failure (US-IJVD in CHF)
Enrolling by invitation NCT00988806 - Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure Phase 4
Recruiting NCT05284955 - Screening for Advanced Heart Failure IN Stable outPatientS - The SAINTS Study (SAINTS B) Phase 4
Completed NCT01643551 - Neuron Specific Enolase in Ventricular Assist Device Recipients N/A
Suspended NCT04851236 - Pilot Study of Massage Therapy to Improve Self Efficacy in Patients With Left-ventricular Device Early Phase 1
Recruiting NCT03526627 - Advanced Care Management in Patients With Advanced Heart Failure
Recruiting NCT06228209 - Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer N/A
Active, not recruiting NCT06259045 - Cardiac Cachexia in Advanced Heart Failure
Recruiting NCT05271214 - Conservative Management of Left Ventricular Assist Device Candidates
Recruiting NCT04475393 - Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure N/A
Recruiting NCT03919136 - Wrist Worn Blood Pressure Measurement
Recruiting NCT03911349 - Wrist Worn Blood Pressure Measurement N/A
Completed NCT01210573 - Prospective Observation of Exercise Parameters in Advanced Heart Failure N/A
Recruiting NCT04423562 - PROgnostic Value of Exercise Capacity Measured as Peak Oxygen Uptake (pVO2) in Recipients of Left Ventricular Assist Devices